医学
前列腺癌
背景(考古学)
谷氨酸羧肽酶Ⅱ
临床试验
医学物理学
核成像
重症监护医学
癌症
肿瘤科
病理
内科学
核医学
古生物学
生物
作者
Steven P. Rowe,Mohammad Salehi Sadaghiani,Andrei Gafita,Sara Sheikhbahaei,Martin G. Pomper,Jeffrey S. Young,Avery Spitz,Rudolf A. Werner,Jorge D. Oldan,Lilja B. Sólnes
标识
DOI:10.1016/j.rcl.2023.07.003
摘要
The discovery and clinical development of radiolabeled small-molecule ligands targeting prostate-specific membrane antigen (PSMA) has had a profound influence on the field of nuclear medicine. Such agents have been successfully deployed for both imaging and therapeutic applications. In particular, PSMA radioligand therapy (PRLT) has been shown to be a life-prolonging therapy for men with metastatic, castration-resistant prostate cancer and has also brought nuclear medicine physicians and nuclear radiologists into the forefront of direct patient care. In this review, we will discuss the clinical study data regarding the efficacy and toxicities related to PRLT, outline the key personnel that any center offering PRLT should have, offer salient clinical examples, and provide an overview of future directions for PRLT. As PRLT continues to evolve as a treatment modality, it is paramount that nuclear medicine physicians and nuclear radiologists understand the clinical context, management implications, and practical aspects so as to best deliver high-value care to patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI